Study Design Guidance Tools
Tools that help guide the design of studies.
- Ransohoff DF. How to improve reliability and efficiency of research about molecular markers: roles of phases, guidelines, and study design. Journal of Clinical Epidemiology 2007;(in press) doi:10.1016/j.jclinepi.2007.04.020.
- Ransohoff DF. Response to commentary. Journal of Clinical Epidemiology 2007;(in press) doi:10.1016/j.jclinepi.2007.07.015.
- Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, Winget M, Yasui Y. Phases of biomarker development for early detection of cancer. Journal of the National Cancer Institute 2001; 93(14):1054-61 (July 18).
- Baker SG, Kramer BS, Srivastava S. Markers for early detection of cancer: Statistical guidelines for nested case-control studies. BMC Medical Research Methodology 2002;2(1):4 (February 28).
- Rules of evidence for cancer molecular-marker discovery and validation
- Bias as a threat to the validity of cancer molecular-marker research
Sample Size Formula and Look-up Tables
The In-person EDRN Orientation Meeting will take place Wednesday, October 19–Friday, October 21, 2016 in Bethesda, MD. More information such as meeting registration and hotel reservations will be sent to new/continuing EDRN members soon.
Update: Pre-application webinar information now available.
The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.
The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.
The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.